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Background: Oral anticoagulant therapy reduces the risk of stroke in patients with atrial fibrillation, but many
patients are still not prescribed this therapy. The causes of underuse of vitamin K antagonists oral anticoagulants
are not clear but could be related, in part, to patients’ and physicians’ perceptions and attitudes towards the
benefits and downsides of this treatment. The purpose of this systematic review was to evaluate and synthesize
patients’ and physicians’ perceptions and attitudes towards the benefits and downsides of vitamin K antagonist,
in order to explore potential factors related with its underuse.
Methods: We included studies that used qualitative or mixed methods and focused on patients’ and/or physicians’
perceptions and attitudes towards oral anticoagulation. We systematically searched PubMed, EMBASE, ISI WoK, and
PsycINFO from their inception until May 2013. Two reviewers independently assessed the quality of the included
studies and synthesized results using a thematic analysis approach.
Results: We included a total of nine studies. In four studies, the quality assessed was excellent and in five was moderate.
We identified three themes that were of interest to both physicians and patients: information to reinforce anticoagulation
use, balance of benefits and downsides, roles in decision-making and therapy management. Three additional themes
were of interest to patients: knowledge and understanding, impact on daily life, and satisfaction with therapy. The main
difficulties with the use of anticoagulant treatment according to physicians were the perceived uncertainty, need of
individualised decision-making, and the feeling of delegated responsibility as their main concerns. The main factors for
patients were the lack of information and understanding.
Conclusion: Physicians’ and patients’ perceptions and attitudes might be potential factors in the underuse of treatment
with vitamin K antagonists. Improving the quality and usability of clinical guidelines, developing tools to help with the
decision-making, enhancing coordination between primary care and hospital care, and improving information provided
to patients could help improve the underuse of anticoagulation.
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Atrial fibrillation or flutter is a common cardiac dis-
order. Estimated prevalence of patients with atrial fibril-
lation was 33.5 million people worldwide in 2010, of
which 20.9 million were men and 12.6 million were
women [1]. Incidence and prevalence are higher in
developed countries and their estimated trends are
growing due to population aging [1, 2]. Age-adjusted
mortality in 2010 was 1.6 and 1.7 per 100,000 for men
and women, respectively [1].
A high risk of stroke is associated with atrial fibrilla-
tion [3–5]. Of all patients that suffer an stroke 20–30%
have atrial fibrillation [6]. Age, a history of previous em-
bolism, heart failure, type 2 diabetes mellitus, hyperten-
sion arteriopathy, and female sex are factors that
increase the risk of embolism among patients with atrial
fibrillation [7, 8]. Atrial fibrillation is a health issue that
is costly for the healthcare system. Costs derive mainly
from hospital admissions (50%) and treatment prescrip-
tion (20%) [9]. Moreover, non-treated patients experi-
ence more complications compared to treated patients
leading to obvious economic consequences [10].
Vitamin K antagonists oral anticoagulants (VKAs) sig-
nificantly reduce the risk of stroke in patients with atrial
fibrillation [8, 11], and are the main group of drugs that
has been historically used for such patients. Neverthe-
less, treatment with VKAs is relatively complex due to
its narrow therapeutic range, which urges regular moni-
torization of the International Normalised Ratio to place
the patient within the optimal range for anti-thrombotic
protection without excessive risk of haemorrhage [6, 12].
Furthermore, VKAs show various drug interactions and,
therefore, no big changes are to be made in the intake of
vitamin K-rich foods. Such specificities of the treatment
with VKAs are some of the potential reasons for its
underuse [13–17] despite concluding evidence available
on its potential net benefit [12, 18].
A new group of oral anticoagulants has recently
emerged as a therapeutic alternative for patients with
atrial fibrillation: the direct oral anticoagulants
(DOACs). Patients taking DOACs show lower risk of
stroke, intracranial bleeding, haemorrhage or death, but
higher risk of gastrointestinal bleeding compared to pa-
tients receiving VKAs [19]. Additionally, patients taking
DOACs show fewer interactions with other drugs and
no interactions with food. However, their effect has a
shorter duration, there is no known antidote and are not
recommended for patients with an important kidney
condition. Moreover, DOACs are considerably more
expensive than VKAs, which is an essential feature to
ensure equal access and treatment adherence [20].
Although the absence of laboratory monitoring for
DOACs might be attractive for patient, it also entails
potential disadvantages, such as the inability to measurethe level of anticoagulation, determine treatment adher-
ence, or detect potential drug interactions [21]. Now-
adays, VKAs continue to be the group of drugs more
frequently used in the common practice for patients
with atrial fibrillation [22].
Previous studies show that preferences of patients’
with atrial fibrillation may be an important reason for
underutilization of oral anticoagulation [23–25]. The
previous systematic review [25] that examined experi-
ences of patients and health providers regarding atrial
fibrillation and treatment with VKAs, revealed a few
factors that might be related to underutilization of
VKAs. Nevertheless, there is no qualitative systematic
review to date focused on knowing patients’ and physi-
cians’ perceptions and attitudes towards VKAs that
might be potential factors for underutilization of VKAs
for atrial fibrillation.
The objective of this qualitative systematic review is to
identify potential factors associated with underuse of
VKAs oral anticoagulants. To do so, we critically synthe-
sised the available qualitative research evidence about
patients’ and physicians’ perceptions and attitudes
towards this treatment alternative.
Methods
We conducted a systematic review to synthesize findings
from studies that assessed patients’ and physicians’ atti-
tudes and perceptions of the risks, benefits, and use of
vitamin K antagonists oral anticoagulants (VKAs), in
order to explore the perceptions and attitudes related to
the underuse of anticoagulation in patients with atrial
fibrillation.
Design
Systematic review of qualitative research.
Data sources
We searched PubMed, EMBASE, ISI Web of Knowledge
(ISI WoK) and PsycINFO from their inception until May
2013. In order to identify relevant publications, a search
using a combination of key words “values or preferences”,
“anticoagulants”, and “atrial fibrillation” was performed.
The search strategy used is in Additional file 1.
Study selection
Two authors independently assessed the references re-
trieved from the search and later resolved any disagree-
ments. We included: i) original articles that explored the
perceptions and attitudes of patients, physicians, or
both, about VKAs for atrial fibrillation; ii) used quali-
tative or mixed methods; and iii) were published in
English, Spanish, German, or French. We excluded
studies that only explored perceptions and attitudes
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studies that did not include qualitative results.
Critical appraisal
We assessed the quality of studies using the Critical
Appraisal Skills Programme (CASP) tool for qualitative
studies [26].
Data extraction and data synthesis
We collected the main characteristics of each study
included in the review (Table 1). We contacted the
authors of the included studies for clarification. We
used a thematic analysis to analyze the data [27]. The
main and recurrent themes, as well as categories,
across the studies were collected systematically. We
segmented the themes and contrasted them between
studies, collapsing and refining the categories per type
of participant (patients and physicians) until the final
result was deemed optimal.
Results
We initially retrieved 1147 references. A total of 1134
publications were excluded after reading the title and
abstract, and 4 were excluded after reading the full
text (Fig. 1). A total of nine articles corresponding to
eight studies were included [28–36]. We also included
a still unpublished study conducted by our group
[37]. Two of the nine studies collected data both
from patients and physicians [29, 37], four collected
data from patients only [28, 32, 33, 35], and three
from physicians only [31, 34, 36]. In four studies, the
quality assessed was excellent [29–31, 35, 37] and in
five was moderate [28, 32–34, 36].
Physicians’ perceptions and attitudes
The five studies with physicians as participants [29, 31,
34, 36, 37] (Table 1) included a total of 91 physicians
(family physicians, cardiologists, geriatrics and internal
medicine physicians). The three main themes that
emerged from the analysis were: I) information to
reinforce anticoagulation use; II) balance of benefits and
downsides; and III) roles in decision-making and therapy
management (Fig. 2).
Information to reinforce anticoagulation use
The information needed to reinforce the vitamin K an-
tagonists (VKAs) use was a theme that emerged in all
five studies including physicians as participants [29, 31,
34, 36, 37].
In three studies [29, 31, 37], some physicians consid-
ered the scientific evidence about VKAs was a possible
barrier for the correct management of anticoagulation
due to the constant changes in the literature [31]. Some
expressed concerns and others justified the prescriptionof aspirin rather than warfarin [31]. Some referred to
their lack of skills in using evidence-based medicine
[31]. They also expressed concerns regarding the applic-
ability of the evidence, which they considered did not in-
clude representative populations, and did not reflect
daily practice [31]. Other comments referred to the need
for more information to reinforce the decision to start
the VKAs [29], the finding of ambiguities in the pub-
lished clinical guidelines [31], and the importance of
individualized decision-making for each patient [31, 37].
In one study [37], physicians stated that they often gave
more weight to their own professional experience than to
research findings for decision-making in VKAs. In relation
to what information physicians should provide to patients,
in one study the opinions ranged on the grade of informa-
tion provided [31], although in another study there was
consensus that generally the way information was given to
patients was inappropriate [29] (Table 2).
Balance of benefits and downsides
Most of the studies discussed the balance of the benefits
and downsides [29, 34, 36, 37]. Physicians expressed no
doubts about the benefits of VKAs [37]. In the Bajorek
study [29], however, geriatricians appeared to be more
focused on the risks than on the benefits. Some physi-
cians expressed uncertainty in specific cases, such as
psychiatric patients, polymedicated patients, patients
that fail to attend follow up, patients at risk of falls
[34, 37], the elderly, and also in certain social envi-
ronments [36, 37] as alcoholic patients [37].
Some family physicians related their uncertainty in the
decision-making of anticoagulation, not only to evidence
but also to the experiences [37] and reactions manifested
by the patients [29]. Some physicians attributed this pa-
tient negativity to the lack of adequate information [36]
or opinions based on hearsay [31]. In one study [36],
physicians’ main concerns about VKAs were the risk of
bleeding and the International Normalized Ratio
monitoring.
Only in one study [31], the physicians directly raised
the topic of safety. Of note, most of the physicians did
not show excessive concerns about safety. Family physi-
cians who were especially concerned about safety
described a lack of clarity in the protocols on safety and
in the International Normalized Ratio monitoring.
Additionally they felt that often the person ultimately
responsible for the treatment was unclear (Table 2).
Roles in decision-making and therapy management
In all studies [29, 31, 34, 36, 37], physicians discussed
decision-making. In three studies [31, 34, 37], most physi-
cians supported shared decision-making; however, the de-
gree of involvement varied [34]. They stated that the
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Table 2 Physicians’ quotations
Information to reinforce anticoagulation use
… although you may have, um, read things, eventually you stick to your
experience, right? You can read that statistically the probability is low but
if you have face a few cases… you don’t act in the same manner.’ (Family
doctor, Spain) [37].
. . . if someone comes to you with atrial fibrillation you want to know, if
he’s the average man in the street, what am I best to treat him with and
that’s . . .that’s not answered by studies that have 80% exclusion rates.”
(Family physician, UK) [29].
Balance of benefits and downsides
“… I believe that in the fibrillation treatment the benefits, I think of those
moments where benefits are observed, regardless of the risk of the therapy
in itself…” (Family physician, Spain) [37].
“Ideally you would want to treat this lady with warfarin but in view of
the recurrent falls and the subsequent risk of life-threatening haemorrhage l
would opt for the lesser antithrombotic of either aspirin or clopidogrel”
(Hospital family physicians, UK) [34].
Roles in decision-making and therapy management
“Patients have wonderful trust in their GPs, which we don’t want to
interfere with, but they do seem to think that the GP is going to remember
and know every detail.” (Hospital pharmacist, Australia) [29].
“…I’m not so much convinced that it should be on me to decide on the
indications, it’s far from clear to me (…), on one hand, and then, I get
really angry when other specialists decide on the indication, which may
be appropriate but they do it with no knowledge of the patient’s social
history whatsoever…” (Family physician, Spain) [37].
Decision making for who goes on warfarin is taken often by one person,
monitoring of warfarin is taken by another person and in our practice people
are monitored in different systems, alright and er . . . ongoing responsibility for
patient education is nonexistent . . . the potential risks of warfarin to me are
so large in terms of errors basically.” (Family physician, UK) [29].
Main themes are captured in bold
Table 3 Patient’s quotations
Knowledge and understanding
A 72-year-old male has a 30 % chance of having a stroke regardless, but
if I didn’t take the Coumadin, it would be a 70 % chance of having one. So
I’m taking medication to avoid the stroke (Patient, Canada) [35].
There was a sticker on one of the medication boxes that said you shouldn’t
take aspirin with this … but the specialist said you take half a Solprin™ …
so you get sort of a conflicting thing (Patient, Australia) [30].
Information to reinforce anticoagulation use
The specialist didn’t give me this [book] … he said that you could get this
book and I had to go to two pharmacists to get one …I think it could be
better communication … they just gave me the book (Patient, Australia)
[30].
I didn’t get anything … only very sketchy in [hospital]… I haven’t received
anything extra at all (Patient, Australia) [30].
Impact of the therapy on daily living
“I had to go get the blood drawn. It was such a pain to get the paperwork
from the doctor’s office and go to the lab to get it drawn, and then you
have to wait to talk to the doctor on the phone. He told you whether or
not to continue it or to change the dosage or what I had to do. And then
you have to go back again to see if it was the proper dose. It was a pain
(Patent, US) [33].
I will only drink one glass of wine a day. I like a glass of wine. They say
just go easy on the single malt, and stuff like that…There wasn’t any
special [instructions regarding diet]. We like good food, and we eat a good,
balanced diet. I like seafood, and I love fish, and I like the odd steak. I try to
stay off butter. I’m taking Becel® just now, which I don’t really like, but I try
to stay off the butter and cooking with all the white sauce, and butter
sauce, and stuff like that (Patient, Canada) [35] .
Balance of benefits and downsides
Before anything the fact of going to the hospital so often, they are crammed
with people, and you have to spend the whole afternoon there… just for
simple shot […] though it’s a real sacrifice (Patient, Spain) [37].
‘With a stroke you’re finished . . .seen lots of my family and friends with a
stroke—it’s terrible’ (Patient, UK) [32].
Roles in decision-making and therapy management
Well, then, I’ve already said I’ll accept what the doctor says. If the doctor
thinks the other option is better, well then, I’ll keep the other option
‘(Patient, Spain) [37].
When I went into the [clinic] to see my doctor, they admitted me to the
cardiac emergency, and they kept me there all day … I was in for just
about a week. … and when I was discharged the doctors explained that
they were putting me on to certain medications, and Coumadin was one
of them (Patient, Canada) [35].
Satisfaction with therapy
I think they’ve been 100 %. From my cardiologist to the family
physician and to the pharmacists, because they’re just amazing.
(Patient, Canada) [35].
I certainly get interactions with different things, but I haven’t been told . . .
[I took] antibiotics for this bad flu that I had . . . no, no I hadn’t [been
warned beforehand] and I was a bit surprised, but once you get the bad
[INR] reading then [the doctor] says, “Oh yeah that was caused by such
and such”. But you already knew that. (Patient, Australia) [29]
Main themes are captured in bold
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that patients preferred to delegate to them [29, 37]. How-
ever, they stressed that patients themselves needed to
assume responsibility for their management [29, 37].
Even some hospital physicians proposed daily Inter-
national Normalized Ratio self-monitoring as the best
option for the patient because it implies a more sus-
tained control [37].
Family physicians also felt specialized physicians dele-
gated responsibility of a complex therapy, traditionally
assigned to hospital professionals [37]. Some family phy-
sicians disagreed on the indications for VKAs given by
hospital physicians [29, 31, 37]. They considered this
disagreement could be associated with the differences
in approach to decision-making: primary care physi-
cians support patient-centered decision-making, while
other specialists are more disease-centered [31, 37].
They also recognized a lack of confidence and experi-
ence prescribing and controlling VKAs, and commu-
nication difficulties with other specialists in case of
doubt, due to the lack of communication channels
[37]. Some specialized physicians also recognized this
lack of communication [36] and suggested that there
should be more communication between primary careand hospitals to reach a consensus on the indications
[37]. Some specialized physicians stated that they also
considered non-clinical characteristics of the patients,
such as psychosocial characteristics [36] (Table 2).
Fig. 1 PRISMA Flowchart
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In the six studies that included patients [28–30, 32, 33, 35,
37] (Table 1) six main themes emerged (Fig. 2): I) knowledge
and understanding; II) information to reinforce anticoagula-
tion use; III) impact of the therapy on daily living; IV) bal-
ance of benefits and downsides; V) roles in decision-making
and therapy management; and VI) satisfaction with therapy.Fig. 2 Emerging themesKnowledge and understanding
In four studies [28, 30, 33, 35] patients discussed the know-
ledge and understanding of VKAs, varying with patient age
(it was higher among younger patients) [35], condition
(lower in patients with atrial fibrillation than in those with
thromboembolism), and setting (lower in patients from
Spain than in patients from the United Kingdom or the
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ies were unaware that VKAs prevents stroke [28, 30, 35]
and in one particular study they did not relate with the risk
of stroke nor with atrial fibrillation [30]. They did not
associate International Normalized Ratio monitoring
with the risk of bleeding or stroke. Only patients
who had had a stroke had full knowledge of the indi-
cations for anticoagulation [30].
Patients expressed some misconceptions, hearsay [30,
33], and myths [29] about alcohol consumption, nutrition,
and concurrent medication [30, 33]. These misunderstand-
ings were likely caused by contradictory recommendations
made by other patients, caregivers, and health care profes-
sionals [30]. Some reported that they had been informed
that VKAs was “a sort of rat poison” [33] (Table 3).
Information to reinforce anticoagulation use
In four studies [29, 30, 35, 37] patients discussed the in-
formation they had received to reinforce VKAs use, with
variable needs on the amount of information they
wanted to receive [37]. In two studies [29, 35], some
patients taking VKAs considered the amount of infor-
mation received was insufficient. They felt that the infor-
mation should be more detailed, especially concerning
drug functioning and dose adjustments [29, 30]. They
requested more information about the role and import-
ance of VKAs, and the implications in accepting this
treatment, at the time of the decision-making [29]. In
another study, patients considered there was a lack of
both written and verbal communication [30].
Patients also manifested difficulties in applying the
knowledge during the daily management of their treat-
ment, and felt they were “on their own” [29]. They
would have preferred to receive the information grad-
ually during follow-up and to be able to check if they
had understood correctly [30], increasing their confi-
dence in its management [29, 30] (Table 3).
Impact of the therapy on daily living
In four studies [30, 33, 35, 37], the issue about the impact of
therapy on daily living emerged. In one study [34], in which
the participants had been taking warfarin, they discussed
about the impact of VKAs and stated that it was small for
most of them. Factors which most concerned patients
were: daily management of VKAs [30, 33, 35, 37]
(dietary restrictions, interactions with other drugs and
alcohol consumption), monitoring, the risk of bleed-
ing [30, 33, 35], the bruises that made them look
older, limitations in certain activities such as sports,
gardening or travelling [33]. Some patients stressed
the changes they had made in their daily lives in
order to manage VKAs [30, 33, 35]. Regarding moni-
toring, some patients stated that it provided them the
feeling of greater control of the disease, while othersreported that it made them feel calm. However, the
more frequently the monitoring takes place, the
greater the perception of the burden is [33] (Table 3).
Balance of benefits and downsides
In all the studies with patients as participants [28, 30,
32, 33, 35, 37], they discussed the benefits and down-
sides. The benefits that some patients associated with
VKAs were: assurance of treatment success, stroke pre-
vention [32] and a chance to live longer [28]. Patients
tended to choose VKAs when they perceived a risk of
stroke [28] or when they had a better understanding of
the conditions associated with anticoagulation (serious
and mild stroke, major bleeding, and the economic costs
and disadvantages of VKAs and aspirin) [37]. In general,
patients who had not taken VKAs based their opinions
on experiences of family members [32, 37], friends [32],
and acquaintances [37]. One study [30] showed that
most patients accepted the therapy, monitoring, dose
changes and compliance with the therapy. However,
some patients [30] considered VKAs treatment was inef-
fective, and those who had not suffered a stroke or were
receiving the therapy for the first time were more
skeptical.
In five studies, the risks of therapy perceived by the
patients were bleeding [30, 32, 33, 35, 37], hematomas
[33], and other adverse effects [30]. In three studies
[30, 33, 35], some patients taking VKAs explained
that they had major bleeding [30, 33, 35]. Two stud-
ies [33, 35] specified that only the minority of partici-
pants had this complication. Regarding bleeding, most
patients in one study [30] expressed no fear of major
bleeding but others expressed anxiety [30]. In two
studies some patients expressed initial fear [30, 37].
In one study [37], patients described thrombotic and
hemorrhagic stroke as a complex condition with serious
or irreversible effects, and they considered it was more
important than major bleeding, economic costs, and the
disadvantages of VKAs and aspirin. In another study,
they considered that hemorrhagic stroke was a final and
permanent state [32]. These perceptions were based on
the experience of family members and friends [32, 37] or
on their own experience [32] (Table 3).
Roles in decision-making and therapy management
In three studies, the patients discussed roles in decision-
making and therapy management [30, 35, 37]. In one
study [30], patients stated that anticoagulation was the
responsibility of both physicians and patients; however,
patients felt that they alone assumed the responsibility
of therapy. In two studies, most patients acknowledged
that decision-making was carried out by the physician
only [35, 37]. This unilateral decision was related to: I)
the patient’s high level of confidence in the physician
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tionship in which the patients were (also) reluctant to
take an active role; and III) the idea that the profes-
sionals were trained and could be more objective [37].
In one study [37], some patients adopted the position of
ignorance and delegated the decision to the professional.
For a small group of patients in one study, the circum-
stances in which this therapy was initiated, as a medical
emergency, prevented any significant patient involve-
ment [35] (Table 3).
Satisfaction with therapy
Satisfaction emerged in three studies [29, 30, 35]. In
one study, patients recognized that their satisfaction
improved when information was given to them indi-
vidually and was focused on care [30]. In another
study, they expressed satisfaction with primary care
staff [35]. Dissatisfaction also appeared in several
studies. Patients expressed dissatisfaction with the
lack of information [29, 35], the quality and level of
the information provided by the family physicians
[30], the difficulties and costs related to monitoring
[35], and health professionals’ lack of knowledge of
their medical history [35] (Table 3).
Discussion
Main findings
In this systematic review evaluating patients and physi-
cians’ perceptions and attitudes towards vitamin K an-
tagonists (VKAs), we identified several themes which
could explain the underuse of VKAs. Physicians regard
uncertainty in specific cases, the need of individualized
decision-making, and the delegated responsibility in
decision making as the main difficulties for using VKAs,
while patients noted the lack of information and under-
standing of VKAs therapy as their main concerns.
Our results in the context of previous research
Three themes –information to reinforce VKAs use,
balance of benefits and downsides, and roles in
decision-making and therapy management– were
common to patients and physicians. The first two
themes were closely related from the perspective of
physicians. Some of them reported uncertainty regard-
ing the balance between benefits and downsides of
VKAs in cases such as polymedicated patients or in
patients at high risk of falls [34, 37]. Despite the
availability of guidelines and research evidence, some
physicians considered that this information did not
always clarify their doubts [31] in a treatment with
narrow therapeutic margins [38]. They identified am-
biguities in some of the guidelines, and stated that
the included populations were not necessarily repre-
sentative of the very elderly, the main candidates foranticoagulation [31]. The participant physicians suggested
the development of individualized decision-making tools
as a strategy to improve this uncertainty [37].
The information to reinforce VKAs use was also re-
lated with decision-making and therapy management
roles, both of patients and physicians. Some of the physi-
cians and most of the patients stated that the actual
decision was generally carried out by physicians only
[29, 35, 37], and that the information received was often
inadequately provided [29] and insufficient [29, 35].
Moreover, in one study some family physicians felt that
specialized physicians delegated the responsibility of de-
cision making to them. These two sources of delegation
were perceived by family physicians as a burden. To
address patient’s delegation, the use at the point of care
of interactive decision aids linked to guidelines could be
a potential strategy [39]. The feeling of family physicians
that specialized physicians delegated the responsibility of
decision making to them could be explained by the lack-
ing certainty about the treatment and the inadequate
exchange of information between them.
A systematic review by Borg et al. that explored pa-
tients’ and health professionals’ experiences on VKAs
therapy, raised the debate of the discrepancy in the per-
ception that patients and health care professionals have
about the decision-making models used in practice [25].
Patients’ experiences suggested a mixed of a paternalistic
and interpretative model (the physician take the deci-
sion, considering the patient’s values and preferences),
while some physicians stated that they practiced shared
decision-making. Our systematic review also observed
this discrepancy to some extent, suggesting that shared
decision–making is not really taking place in clinical
practice.
Knowledge and understanding of the therapy was an
important issue that arose among patients only. One
study included in our systematic review shows that the
knowledge and understanding was worse in elderly pa-
tients than younger [30]. Given that most patients with
atrial fibrillation are of advance age, to be able to make
an informed decision, it is especially important that the
information is provided and explained appropriately.
Moreover, it is crucial to improve the quality of the in-
formation provided to patients because it is the main
factor of dissatisfaction with the therapy [12, 27, 30].
Better information will improve understanding and is
likely to increase the use of anticoagulation [37]. One of
the factors that may explain why the difficulties with un-
derstanding of the anticoagulant treatment are greater
for the elderly is that they generally are less educated
[40], although this fact is changing.
Like one of our studies shows, patients tend to choose
treatment with VKAs when they have a better understan-
ding of the conditions associated with anticoagulation [37].
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essential for patients to assess the benefits and downsides
based on their preferences [37].
A previous systematic review of quantitative studies
that evaluated patients’ preferences for anticoagulants
including direct oral anticoagulants (DOACs), agrees
with our review that, considering the different anti-
coagulant treatments, patients’ preferences are based
mainly on clinical aspects (reduction in the risk of stroke
and moderate increase in the risk of bleeding). Never-
theless, whenever the different treatment options offer
similar security and efficacy, convenience takes on im-
portance for the decision making, such as once-a-day
administration or no interactions with drugs or food.
The need for monitorization of VKAs is sometimes
perceived positively and sometimes negatively [41].
Limitations and strengths
The main limitation of our study is that we cannot confirm
a relationship between the factors identified and underuse
of VKAs therapy [42]. Another limitation was that there
were two studies which did not only included physicians
and patients as participants –nurses, pharmacist, and
carers participated too. Only in some cases we were able to
exclude the data coming from participants other than our
target groups [29, 30, 36]. Also, in one of the studies [27] it
was not always possible to differentiate between patients
and physicians for some of the results reported.
The review does not include studies on patients’
perceptions and attitudes towards DOACs. Neverthe-
less, treatment with VKAs continues to be the main
group of drugs used. Additionally, a great part of the
emerging deficits in the treatment with VKAs would
be applicable to the treatment with DOACs, since
said deficits are more related to the healthcare sys-
tems, like the lack of information provided to patients
or difficulties with the coordination between primary
care and hospital care.
Finally, a potential limitation is the fact that further
data sources like CINAHL have not been searched.
However, we believe that this may be a minor limitation
since we have searched biomedical data sources with a
wider and more detailed scope.
The main strength of our review is that it is the first
qualitative systematic review to specifically explore fac-
tors potentially related to the underuse of oral anticoa-
gulation in atrial fibrillation. Moreover, our review
includes two more studies [36, 37] than Borg’s system-
atic review [25]. Another strength of our work is the re-
search team expertise, as it includes a multidisciplinary
group of experts in oral anticoagulation therapy,
Evidence-Based Medicine, and qualitative research. The
group also includes several authors of one of the in-
cluded studies.Implications for practice and research
To tackle the underuse of anticoagulation there is a need
to improve the quality and usability of clinical guide-
lines, and of the information that is provided to patients;
as well as to enhance the coordination between primary
care and hospital care. Linking evidence-based guide-
lines with decision aids could be a way forward to
engage patients and physicians in shared decision-
making [39]. Both guidelines and tools should be user-
friendly, interactive, and based on the most rigorous
evidence.
We identified some of the differences between family
physicians and specialized physicians. However, further
studies are needed to explore in more depth this issue.
Moreover, qualitative studies evaluating the perceptions
and attitudes about the direct anticoagulants should also
be carried out.
Conclusion
Physicians perceived uncertainty, need of individualized
decision-making, and the feeling of delegated responsi-
bility, as their main concerns that may be related to
underuse of vitamin K antagonists, while for patients the
main factors were the lack of information and under-
standing. Improving the quality and usability of clinical
guidelines, the information provided to patients (e.g.
linking decision aids and guidelines), developing tools to
facilitate shared decision-making, and enhancing the co-
ordination between primary care and hospital care could
help improve the underuse of this important treatment
option in patients with atrial fibrillation.
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